Compare Amphastar Pharmaceuticals Inc (AMPH) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FNGU trades at $28.64, up 0.77% on the day, with technical indicators showing a bullish trend from moving averages but caution from oscillators like the 6-day RSI at 95.66. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the leveraged ETN's high-risk nature. The asset lacks traditional fundamental metrics like P/E or revenue data, as it is an exchange-traded note tracking the FANG+ Index with 3x leverage.

The outlook for FNGU is highly speculative, driven by momentum in tech stocks but fraught with decay risks from daily rebalancing. Opportunities exist for short-term traders betting on Nasdaq-100 rallies, while risks include rapid capital erosion during market downturns, as evidenced by recent losses. Investors must understand the product's structure to avoid unintended losses.